FOR IMMEDIATE RELEASE

Cephalon Announces Roll Out of *AMRIX*, the First and Only Skeletal Muscle Relaxant with Once-Daily Dosing

Frazer, Pa – October 3, 2007 – Cephalon, Inc. (Nasdaq: CEPH) will begin to make *AMRIX*™ (Cyclobenzaprine Hydrochloride Extended-Release Capsules) available to pharmacies in the United States in October. *AMRIX*, the first and only once-daily formulation of the skeletal muscle relaxant cyclobenzaprine hydrochloride, was approved by the U.S. Food and Drug Administration in February 2007 for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. The medication is intended for short-term use (up to two or three weeks). The full product launch is scheduled for November. Once pharmacies are fully stocked, *AMRIX* will be available in 15 mg and 30 mg dosage strengths.

NDC Codes for *AMRIX*	
DESCRIPTION	**NDC #**
AMRIX 15 mg Bottles of 60	00095-0150-06
AMRIX 30 mg Bottles of 60	00095-0300-06

About *AMRIX*

AMRIX provides convenient once-daily dosing that can be taken in the daytime or at nighttime. *AMRIX* should be taken at approximately the same time every day. *AMRIX* provides early systemic exposure of cyclobenzaprine followed by consistent plasma levels, reducing fluctuations over its 24-hour dosing period. In a pooled analysis of the two phase 3 clinical trials, *AMRIX* demonstrated a statistically significant difference in patients' rating of medication helpfulness versus placebo at day four of treatment. Patient recordings were made in the evening prior to next dose.

In clinical trials, *AMRIX* was found to be generally well tolerated. In the pooled analysis, the most common adverse reactions seen in ≥3 percent of patients treated with *AMRIX* were dry mouth, dizziness, fatigue, nausea, dyspepsia (indigestion), and constipation. At day four, daytime drowsiness reported in patients taking either the 15 mg or 30 mg doses of *AMRIX*, in the evening, was greater than placebo and less than the 10 mg dose of immediate-release cyclobenzaprine taken three times daily.

AMRIX is indicated as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion.

AMRIX should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.

AMRIX has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.

AMRIX is contraindicated in patients concomitantly using monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation; in patients during the acute recovery phase of myocardial infarction (heart attack); in patients with arrhythmias (irregular heart beat), heart block conduction disturbances or congestive heart failure; and in patients with hyperthyroidism. *AMRIX* should not be used in elderly patients or in those with hepatic (liver) impairment.

AMRIX is distributed by Cephalon and produced with Eurand Diffucaps® technology which provides extended release of cyclobenzaprine hydrochloride to permit once-daily dosing.

Full prescribing information is available at www.amrix.com.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company, ranked as one of the top 10 companies in its field. For 20 years, the company has been dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75% and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL® (modafinil) Tablets [C-IV], FENTORA® (fentanyl buccal tablet) [C-II], TRISENOX® (arsenic trioxide) injection, AMRIX, VIVITROL® (naltrexone for extended-release injectable suspension), GABITRIL® (tiagabine hydrochloride), NUVIGIL™ (armodafinil) Tablets [C-IV] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at www.cephalon.com or by calling 1-800-896-5855.